- Irsogladine maleate
-
- $1.00
-
2026-02-02
- CAS:84504-69-8
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- Irsogladine maleate
-
- $35.00
-
2024-03-16
- CAS:84504-69-8
- Min. Order: 1kg
- Purity: 99.8%
- Supply Ability: 200tons/year
|
| | Irsogladine maleate Basic information |
| Product Name: | Irsogladine maleate | | Synonyms: | 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazinemaleate;2,4-diamino-6-(2,5-dichlorophenyl)-s-triazinmaleate;3,5-triazine-2,4-diamine,6-(2,5-dichlorophenyl)-(z)-2-butenedioate(1:1);gaslon;mn-1695;2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine maleate;Irsogladin maleate;Gaslon N | | CAS: | 84504-69-8 | | MF: | C13H11Cl2N5O4 | | MW: | 372.16 | | EINECS: | | | Product Categories: | Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 84504-69-8.mol |  |
| | Irsogladine maleate Chemical Properties |
| Melting point | 181-182°C | | storage temp. | Inert atmosphere,Room Temperature | | Water Solubility | Insoluble in water | | solubility | DMF:30.0(Max Conc. mg/mL);80.61(Max Conc. mM)
DMSO:30.0(Max Conc. mg/mL);80.61(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.67(Max Conc. mM) | | form | White crystalline powder. | | color | White to Almost white | | Merck | 14,5102 | | InChI | InChI=1S/C9H7Cl2N5.C4H4O4/c10-4-1-2-6(11)5(3-4)7-14-8(12)16-9(13)15-7;5-3(6)1-2-4(7)8/h1-3H,(H4,12,13,14,15,16);1-2H,(H,5,6)(H,7,8)/b;2-1- | | InChIKey | PJLVTVAIERNDEQ-BTJKTKAUSA-N | | SMILES | N1=C(C2=CC(Cl)=CC=C2Cl)N=C(N)N=C1N.C(O)(=O)/C=C\C(O)=O | | CAS DataBase Reference | 84504-69-8(CAS DataBase Reference) |
| WGK Germany | WGK 3 | | RTECS | XY5930000 | | HS Code | 2933.69.6050 | | Storage Class | 11 - Combustible Solids | | Toxicity | LD50 in male, female mice, rats (mg/kg): 6035, 5697, 3898, 2917 orally; 2841, 3216, 1600, 1524 s.c.; 775, 1006, 558, 545 i.p. (Ueda, 1984 p 474) |
| | Irsogladine maleate Usage And Synthesis |
| Description | Irsogladine is a gastroprotective agent. It increases transfer of Lucifer yellow CH between isolated rabbit gastric epithelial cells, indicating enhanced gap junction intercellular communication (GJIC). Irsogladine (3 mg/kg) inhibits gastric mucosal lesion formation and decreases in gastric mucosal blood flow induced by monochloramine in rats, effects that can be prevented by the nitric oxide synthase inhibitor L-NAME . It also inhibits superoxide anion production induced by fMLP and increases cAMP levels in isolated human neutrophils in a concentration-dependent manner, similar to the phosphodiesterase 4 (PDE4) inhibitor rolipram . | | Chemical Properties | White Solid | | Uses | An anti-ulcer drug. Potent PDE4 inhibitor | | Uses | antiulcerative;selective PDE4 inhibitor which also enhances gap junction intercellular communication | | Definition | ChEBI: Irsogladine maleate is a dichlorobenzene. | | Biological Activity | Phosphodiesterase 4 (PDE4) inhibitor that displays gastroprotective properties. Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion. Activates gap-junctional intercellular communication improving gastric mucosal barrier function. Inhibits superoxide production in human neutrophils and inhibits in vitro and in vivo angiogenesis. | | References | [1] TAKASHI KYOI. Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.[J]. Journal of pharmacological sciences, 2003, 93 3: 314-320. DOI: 10.1254/jphs.93.314
[2] F UEDA T I K Ban. Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor.[J]. Journal of Pharmacology and Experimental Therapeutics, 1995, 274 2: 815-819.
[3] TAKASHI KYOI. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils[J]. Life sciences, 2004, 76 1: Pages 71-83. DOI: 10.1016/j.lfs.2004.06.016 |
| | Irsogladine maleate Preparation Products And Raw materials |
|